PhytoNexus

PhytoNexus

Department of Pharmacognosy · Herb-Drug Interaction Intelligence Platform · generated 27 Jul 2026 01:04 IST
Fabaceae · source entry 289

Astragalus membranaceus

Astragalus

Tier 1 · chemistry only 0 curated · 7 predicted 4Contraindicated Risk index 75.2
Interaction profile
Tier 1 entry. Taxonomy, plant part and marker chemistry are populated and stable. The clinical columns are deliberately empty because no primary source has been retrieved for them yet. Interactions shown below are rule predictions from the constituent chemistry, not clinical findings.

01 Identity and provenance

Accepted binomial
Astragalus membranaceus
Common names
Astragalus
Family (APG IV)
Fabaceae
Part used
Root
Verification tier
Tier 1 · chemistry only Taxonomy, plant part and marker chemistry are populated and stable. The clinical columns are deliberately empty because no primary source has been retrieved for them yet. Interactions shown below are rule predictions from the constituent chemistry, not clinical findings.
Reviewer note (2026 audit)
TIER 1 populated (name, family, part, constituent class, marker) - stable taxonomic/phytochemical facts. TIER 2 columns (analogue, application, brand, interactions, side effects) left blank BY DESIGN - populate only from retrieved primary literature. Do not use clinically until Tier 2 is filled and a reference is recorded.

02 Constituent chemistry

Chemical classMarker compoundSynthetic analogue in use
Triterpenoid saponins, polysaccharides Astragaloside IV
Root
none listed

The analogue column is what makes the interaction reasoning tractable: where a constituent has a marketed structural counterpart, the counterpart's interaction profile is the starting hypothesis for the plant.

Looking up structures and physicochemical properties from PubChem…

03 Stated application

Left empty by design — this is a Tier 1 entry, and the clinical columns are only populated once a primary source has been retrieved for them.

04 Interaction matrix

Predicted from constituent chemistry

These edges are not clinical findings. Each one is a rule inference: a constituent class in this plant is known to act on a target that the drug class also acts on. They are shown because a blank cell reads as “safe”, and for a Tier 1 entry a blank cell only means “not yet looked at”. Treat them as a literature-search agenda, not as a warning.
Drug classSeverityMechanism type ProvenanceExpected effect
Cardiac glycosides (digoxin, digitoxin)
Cardiovascular
4Contraindicated PD-additive + PK-transporter + assay interference predicted D Nausea, xanthopsia, bradyarrhythmia, AV block, ventricular tachycardia an… why ▾
Antidiabetic drugs (insulin, sulfonylureas, biguanides, GLP-1, SGLT2)
Endocrine
3Major PD-additive predicted D Symptomatic hypoglycaemia, sweating, tremor, confusion; severe events rep… why ▾
Antiplatelet agents
Haemostasis
3Major PD-additive predicted D Prolonged bleeding time, surgical and post-procedural bleeding, bruising,… why ▾
Hormonal therapy, oral contraceptives and HRT
Endocrine
3Major PK-CYP3A4 induction + PD-oestrogenic predicted D Breakthrough bleeding and contraceptive failure; unpredictable effect in … why ▾
Antibacterials and anthelmintics
Infection
2Moderate PK-chelation + PK-CYP predicted D Treatment failure from subtherapeutic antibiotic concentrations, or raise… why ▾
Iron, calcium and mineral supplements
Nutrition
2Moderate PK-chelation predicted D Failure of iron-deficiency correction, unexplained non-response to oral i… why ▾
Thyroid hormones and antithyroid drugs
Endocrine
2Moderate PK-absorption + PD-modulation predicted D Iatrogenic hyper- or hypothyroidism, unexplained TSH drift, loss of euthy… why ▾

05 Hazard register

The audit recorded no hazard beyond the interaction profile. The controlled-vocabulary field reads not assessed, which means the assessment has not been done rather than that it came back clear.

06 Confusable material

These entries could be mistaken for this one in trade, in the herbarium, or in a prescription. Powdered material is often indistinguishable, so the check is macroscopic, microscopic and chromatographic rather than nominal.

Astragalus gummifer
Tragacanth
Fabaceae Same genus (Astragalus)

07 Mechanism map

Chemistry sorts to the left, pharmacology to the right. Dashed edges are predicted. Drag nodes, scroll to zoom, export at 3× for a figure.

species
chemical class
marker compound
drug class
expected effect
hazard

08 Open literature

Abstract-scoped query built from this binomial, its common names and its marker compounds, run live against Europe PMC, PubMed and OpenAlex, then ranked locally against an evidence hierarchy.

Checking openFDA spontaneous reports…

09 Isomechanistic neighbours

Species whose interaction profile overlaps this one, ranked by shared severity weight rather than by count — a shared contraindication counts for more than a shared minor signal. Practical use: these are the plants you should not stack with this one, because the mechanisms summate.

SpeciesFamilyShared classes WeightJaccard
Trigonella foenum-graecum
Fenugreek
Fabaceae 7 1.00
Panax ginseng
Ginseng
Araliaceae 7 0.70
Echinacea purpurea
Echinacea
Asteraceae 6 0.46
Linum usitatissimum
Flax (Alsi)
Linaceae 6 0.75
Phyllanthus amarus
Bhui Amla
Phyllanthaceae 6 0.46
Senegalia senegal
Gum Acacia
Fabaceae 5 0.71

10 References and notes

No citation is on record for this entry. That is itself the finding: the audit flagged it, and it is why the entry does not carry an A evidence grade.

Curator notes

No notes yet.

Sign in to add notes and save monographs.